22 October 2015 - The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468654.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery